Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to €4.36, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 18x in the Medical Equipment industry in Germany. Total loss to shareholders of 70% over the past three years. Recent Insider Transactions • Aug 13
President recently bought €122k worth of stock On the 12th of August, Devdatt Kurdikar bought around 30k shares on-market at roughly €4.07 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Devdatt's only on-market trade for the last 12 months. Reported Earnings • Aug 09
Third quarter 2026 earnings released: EPS: US$0.36 (vs US$0.78 in 3Q 2025) Third quarter 2026 results: EPS: US$0.36 (down from US$0.78 in 3Q 2025). Revenue: US$271.7m (down 8.1% from 3Q 2025). Net income: US$21.1m (down 54% from 3Q 2025). Profit margin: 7.8% (down from 15% in 3Q 2025). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 05
Embecta Corp Faces Securities Fraud Class Action Lawsuit Embecta Corp. had a securities fraud class action lawsuit filed against it and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. Key Details of the Embecta Class Action: Lead Plaintiff Deadline: August 17, 2026. Alleged Misconduct: Securities fraud relating to Embecta’s statements about the strength of its insulin pen needle product category. Largest Alleged Stock Drop: May 5, 2026 – 57.8% Stock Drop. Court: U.S. District Court for the District of New Jersey. Investors have until August 17, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Apitz-Grossman v. Embecta Corp., et al., No. 26-cv-07217. Embecta is a medical device company that produces insulin pens for patients with diabetes. According to the complaint, during the relevant period, Embecta touted the strength of its insulin pen portfolio stating that prescriptions for insulin pens have been showing a slight positive trend just exemplifying the resilience of this product portfolio. As alleged, in truth, Embecta faced significant competition and overall market softness for insulin pens and pen needles. On May 5, 2026, Embecta announced disappointing Second Quarter 2026 results that came in below guidance due to share loss within its pen needle product category, most of which was from a single customer. Embecta also reported an overall market volume softness for insulin pens and pen needles in the retail channel, admitting that company have now begun to see a decline [for insulin pens] maybe more pronounced in the most recent quarter that company reported. As a result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per share. This news caused the price of Embecta common stock to decline $5.35 per share, or 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Tillkännagivande • Jul 24
Embecta Corp. to Report Q3, 2026 Results on Aug 07, 2026 Embecta Corp. announced that they will report Q3, 2026 results Pre-Market on Aug 07, 2026 Tillkännagivande • Jun 16
Embecta Corp. Announces Appointment of Nimish Muzumdar to Senior Vice President and President, North America, Effective June 15, 2026 Embecta Corp. announced that Nimish Muzumdar has been named the company’s Senior Vice President and President, North America, effective June 15, 2026. Mr. Muzumdar will be responsible for leading the United States and Canada commercial teams and executing the region’s long-term growth strategy. He will report to Dev Kurdikar, Chairman, President and CEO of embecta, and serve on the embecta Operating Team. Mr. Muzumdar most recently served as Senior Vice President & Head, Generics (Retail, Institutional, Hospitals & Clinics) at Sandoz — a $1 billion division that he returned to sustained, profitable growth. Following its spinoff from Novartis in 2023, he helped shape the organization’s commercial strategy, culture, and operational foundation for long-term success. In his decade-plus at Sandoz, he previously served as Director, Generics Oncology & Injectables; Executive Director, Generics Oncology & Injectables; and Executive Director, Retail Generics. Prior to Sandoz, he held marketing roles of increasing leadership responsibility for Ranbaxy USA, Watson Laboratories, and Dr. Reddy’s Laboratories. Mr. Muzumdar holds a Bachelor of Science – Pharmacy from the University of Mumbai and an MBA from New York Institute of Technology. Board Change • May 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Lead Independent Director Claire Pomeroy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 06
Embecta Corp. (NasdaqGS:EMBC) announces an Equity Buyback for $100 million worth of its shares. Embecta Corp. (NasdaqGS:EMBC) announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its stock. The program is valid for 3 years. Tillkännagivande • Feb 12
Embecta Announces Board Changes, Effective February 11, 2026 Embecta announced that its board of directors elected the company’s CEO, Devdatt “Dev” Kurdikar, as chair. The Parsippany, New Jersey-based BD Diabetes spinoff also named Dr. Claire Pomeroy as lead independent director. Both appointments go into effect immediately. These changes follow the retirement of David Melcher, who previously served as non-executive chair of the board. Kurdikar,57, joined BD in 2021 to join the company’s diabetes care business, overseeing it during its separation from the medtech giant. He assumed the role of president and CEO of Embecta following the 2022 spin-off, also joining the company’s board. Changes come atop the company’s board as Embecta works through brand transition program through a phased plan to create value and shift priorities toward broader medical applications. Pomeroy,70, joined Embecta’s board of directors at its inception in 2022. In addition to serving as lead independent director, she will continue to chair the board’s Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee. Other roles for Pomeroy include president of the Albert and Mary Lasker Foundation, a private foundation. It seeks to improve health by accelerating support for medical research through research excellence, public education and advocacy. Pomeroy also serves as a director of Haemonetics and on a number of other boards across several foundations, centers, labs, schools and more. Tillkännagivande • Feb 06
Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026 Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. Tillkännagivande • Dec 19
Embecta Corp., Annual General Meeting, Feb 11, 2026 Embecta Corp., Annual General Meeting, Feb 11, 2026. Tillkännagivande • Nov 18
Embecta Corp. Announces Board Changes Embecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company. Tillkännagivande • Nov 12
Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025 Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025 Tillkännagivande • Aug 08
Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025 The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. Tillkännagivande • May 22
Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025 Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million. Tillkännagivande • Apr 22
Embecta Corp. to Report Q2, 2025 Results on May 09, 2025 Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025 Tillkännagivande • Jan 24
Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025 Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025 Tillkännagivande • Dec 20
Embecta Corp., Annual General Meeting, Feb 12, 2025 Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United States Tillkännagivande • Dec 03
Embecta Corp. Announces Executive Changes Embecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer. Tillkännagivande • Dec 01
Embecta Corp. announced delayed annual 10-K filing On 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Nov 13
Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024 Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024 Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €14.90, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 10% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €28.37 per share. Tillkännagivande • Sep 03
Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery System Embecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission. Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €13.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 13% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €22.16 per share. Upcoming Dividend • Aug 21
Upcoming dividend of US$0.15 per share Eligible shareholders must have bought the stock before 27 August 2024. Payment date: 13 September 2024. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 4.4%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.9%). Declared Dividend • Aug 15
Third quarter dividend of US$0.15 announced Shareholders will receive a dividend of US$0.15. Ex-date: 27th August 2024 Payment date: 13th September 2024 Dividend yield will be 4.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (253% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. EPS is expected to grow by 61% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 11
Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.27 in 3Q 2023) Third quarter 2024 results: EPS: US$0.25 (down from US$0.27 in 3Q 2023). Revenue: US$272.5m (down 4.8% from 3Q 2023). Net income: US$14.7m (down 3.3% from 3Q 2023). Profit margin: 5.4% (up from 5.3% in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. New Risk • Jul 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-US$770m). Minor Risks Dividend is not well covered by cash flows (368% cash payout ratio). Large one-off items impacting financial results. Tillkännagivande • Jul 19
Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024 Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024 Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €11.90, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.25 per share. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to €13.30, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 46% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.81 per share. Declared Dividend • May 13
Second quarter dividend of US$0.15 announced Shareholders will receive a dividend of US$0.15. Ex-date: 24th May 2024 Payment date: 14th June 2024 Dividend yield will be 4.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (368% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • May 10
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Negative equity (-US$770m). Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. Minor Risks Dividend is not well covered by cash flows (368% cash payout ratio). Share price has been volatile over the past 3 months (9.0% average weekly change). Reported Earnings • May 10
Second quarter 2024 earnings released: EPS: US$0.50 (vs US$0.24 in 2Q 2023) Second quarter 2024 results: EPS: US$0.50 (up from US$0.24 in 2Q 2023). Revenue: US$287.2m (up 3.6% from 2Q 2023). Net income: US$28.9m (up 106% from 2Q 2023). Profit margin: 10% (up from 5.1% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 7.0% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Apr 24
Embecta Corp. to Report Q2, 2024 Results on May 09, 2024 Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024 Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.01 per share. Upcoming Dividend • Feb 20
Upcoming dividend of US$0.15 per share Eligible shareholders must have bought the stock before 27 February 2024. Payment date: 15 March 2024. Payout ratio is a comfortable 62% but the company is not cash flow positive. Trailing yield: 4.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%). Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to €13.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past year. Declared Dividend • Feb 14
First quarter dividend of US$0.15 announced Shareholders will receive a dividend of US$0.15. Ex-date: 27th February 2024 Payment date: 15th March 2024 Dividend yield will be 4.2%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (62% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 111% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 11
First quarter 2024 earnings released: EPS: US$0.35 (vs US$0.62 in 1Q 2023) First quarter 2024 results: EPS: US$0.35 (down from US$0.62 in 1Q 2023). Revenue: US$277.3m (flat on 1Q 2023). Net income: US$20.1m (down 43% from 1Q 2023). Profit margin: 7.2% (down from 13% in 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. New Risk • Feb 10
New major risk - Revenue and earnings growth Earnings have declined by 40% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Negative equity (-US$822m). Earnings have declined by 40% per year over the past 5 years. Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Profit margins are more than 30% lower than last year (6.3% net profit margin). Tillkännagivande • Jan 25
Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024 Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024 Tillkännagivande • Jan 09
Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch Pump Embecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission. Tillkännagivande • Dec 20
Embecta Corp., Annual General Meeting, Feb 07, 2024 Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan. Reported Earnings • Nov 23
Full year 2023 earnings released: EPS: US$1.23 (vs US$3.92 in FY 2022) Full year 2023 results: EPS: US$1.23 (down from US$3.92 in FY 2022). Revenue: US$1.12b (flat on FY 2022). Net income: US$70.4m (down 69% from FY 2022). Profit margin: 6.3% (down from 20% in FY 2022). Revenue is forecast to stay flat during the next 2 years compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. New Risk • Nov 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Negative equity (-US$809m). Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.2% net profit margin). Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €15.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past year. Upcoming Dividend • Aug 17
Upcoming dividend of US$0.15 per share at 3.2% yield Eligible shareholders must have bought the stock before 24 August 2023. Payment date: 13 September 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.9%). Reported Earnings • Aug 09
Third quarter 2023 earnings released: EPS: US$0.27 (vs US$1.08 in 3Q 2022) Third quarter 2023 results: EPS: US$0.27 (down from US$1.08 in 3Q 2022). Revenue: US$286.1m (down 1.7% from 3Q 2022). Net income: US$15.2m (down 76% from 3Q 2022). Profit margin: 5.3% (down from 21% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Jul 06
Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023 On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023. Reported Earnings • May 14
Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022) Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Recent Insider Transactions • Feb 20
Independent Non-Executive Chairman recently bought €96k worth of stock On the 15th of February, David Melcher bought around 3k shares on-market at roughly €30.85 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months. Recent Insider Transactions • Feb 17
Independent Non-Executive Chairman recently bought €94k worth of stock On the 15th of February, David Melcher bought around 3k shares on-market at roughly €30.47 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months. Reported Earnings • Feb 15
First quarter 2023 earnings released First quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €24.40, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Tillkännagivande • Jan 25
Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023 Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023 Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment deteriorated over the past week After last week's 20% share price decline to €24.00, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Reported Earnings • Dec 24
Full year 2022 earnings released Full year 2022 results: EPS: US$3.92. Revenue: US$1.13b (down 3.0% from FY 2021). Net income: US$223.6m (down 46% from FY 2021). Profit margin: 20% (down from 36% in FY 2021). The decrease in margin was primarily driven by higher expenses. Revenue is expected to decline by 2.8% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Germany are expected to grow by 5.5%. Board Change • Nov 16
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Oct 28
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Oct 01
Embecta Corp., Annual General Meeting, Feb 09, 2023 Embecta Corp., Annual General Meeting, Feb 09, 2023. Tillkännagivande • Sep 19
Embecta Corp.(NasdaqGS:EMBC) dropped from FTSE All-World Index (USD) Embecta Corp.(NasdaqGS:EMBC) dropped from FTSE All-World Index (USD) Reported Earnings • Aug 17
Third quarter 2022 earnings released Third quarter 2022 results: EPS: US$1.08. Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 3.1% compared to a 7.6% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Aug 16
Embecta Corp. Revises Revenue Guidance for the Second-Half Fiscal Year 2022 Embecta Corp. revised revenue guidance for the Second-Half Fiscal Year 2022. For the period, the company expects Revenues of approximately $555 million compared to $555 million previous guidance. 
